These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 31172910)
41. Clostridium difficile shows no trade-off between toxin and spore production within the human host. Blanco N; Walk S; Malani AN; Rickard A; Benn M; Eisenberg M; Zhang M; Foxman B J Med Microbiol; 2018 May; 67(5):631-640. PubMed ID: 29533173 [TBL] [Abstract][Full Text] [Related]
42. Toxin synthesis by Clostridium difficile is regulated through quorum signaling. Darkoh C; DuPont HL; Norris SJ; Kaplan HB mBio; 2015 Feb; 6(2):e02569. PubMed ID: 25714717 [TBL] [Abstract][Full Text] [Related]
43. Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen. Awad MM; Johanesen PA; Carter GP; Rose E; Lyras D Gut Microbes; 2014; 5(5):579-93. PubMed ID: 25483328 [TBL] [Abstract][Full Text] [Related]
44. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital]. Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153 [TBL] [Abstract][Full Text] [Related]
45. Carvacrol and trans-cinnamaldehyde reduce Clostridium difficile toxin production and cytotoxicity in vitro. Mooyottu S; Kollanoor-Johny A; Flock G; Bouillaut L; Upadhyay A; Sonenshein AL; Venkitanarayanan K Int J Mol Sci; 2014 Mar; 15(3):4415-30. PubMed ID: 24625665 [TBL] [Abstract][Full Text] [Related]
46. [Antimicrobial susceptibilities and molecular characterization of toxin-positive Clostridium difficile isolates: the first report on the presence of hypervirulent strains from Turkey]. Salman E; Levent B; Karahan ZC Mikrobiyol Bul; 2017 Jul; 51(3):236-246. PubMed ID: 28929960 [TBL] [Abstract][Full Text] [Related]
47. Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Vohra P; Poxton IR Microbiology (Reading); 2011 May; 157(Pt 5):1343-1353. PubMed ID: 21330434 [TBL] [Abstract][Full Text] [Related]
48. Antibacterial activity of rhodomyrtone on Clostridium difficile vegetative cells and spores in vitro. Srisuwan S; Mackin KE; Hocking D; Lyras D; Bennett-Wood V; Voravuthikunchai SP; Robins-Browne RM Int J Antimicrob Agents; 2018 Nov; 52(5):724-729. PubMed ID: 30145248 [TBL] [Abstract][Full Text] [Related]
49. Uptake and levels of the antibiotic berberine in individual dormant and germinating Clostridium difficile and Bacillus cereus spores as measured by laser tweezers Raman spectroscopy. Wang S; Setlow B; Setlow P; Li YQ J Antimicrob Chemother; 2016 Jun; 71(6):1540-6. PubMed ID: 26861569 [TBL] [Abstract][Full Text] [Related]
50. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile. Skinner K; Birchall S; Corbett D; Thommes P; Locher HH J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178 [TBL] [Abstract][Full Text] [Related]
51. A Clostridium difficile-Specific, Gel-Forming Protein Required for Optimal Spore Germination. Donnelly ML; Li W; Li YQ; Hinkel L; Setlow P; Shen A mBio; 2017 Jan; 8(1):. PubMed ID: 28096487 [TBL] [Abstract][Full Text] [Related]
56. Molecular methods to study transcriptional regulation of Clostridium difficile toxin genes. Antunes A; Dupuy B Methods Mol Biol; 2010; 646():93-115. PubMed ID: 20597005 [TBL] [Abstract][Full Text] [Related]
57. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Endres BT; Bassères E; Khaleduzzaman M; Alam MJ; Chesnel L; Garey KW Antimicrob Agents Chemother; 2016 Jun; 60(6):3519-23. PubMed ID: 27021314 [TBL] [Abstract][Full Text] [Related]
58. In vitro production of Clostridium difficile spores for use in the efficacy evaluation of disinfectants: a precollaborative investigation. Hasan JA; Japal KM; Christensen ER; Samalot-Freire LC J AOAC Int; 2011; 94(1):259-72. PubMed ID: 21391503 [TBL] [Abstract][Full Text] [Related]
59. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. Jiang ZD; DuPont HL; La Rocco M; Garey KW J Clin Pathol; 2010 Apr; 63(4):355-8. PubMed ID: 20354207 [TBL] [Abstract][Full Text] [Related]
60. Inactivation of Clostridium difficile spore outgrowth by synergistic effects of nisin and lysozyme. Chai C; Lee KS; Imm GS; Kim YS; Oh SW Can J Microbiol; 2017 Jul; 63(7):638-643. PubMed ID: 28346844 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]